Tislelizumab 100mg/10mL Injection

Product Introduction

Tislelizumab 100mg/10mL is an immune-checkpoint treatment used for advanced cancers including non-small cell lung cancer and oesophageal squamous-cell carcinoma. The cancer type, biomarker results and previous treatment determine whether it is used alone or with chemotherapy.

How to use

The concentrate is diluted and given by intravenous infusion in an oncology unit. The first infusion is generally given over 60 minutes; later infusions may be shorter if well tolerated. The dose and interval depend on the cancer regimen, rather than the 100mg vial size alone.

How it works

Tislelizumab blocks PD-1, an immune checkpoint on T cells. This prevents tumour-associated signals from switching off T-cell activity and helps restore an immune response against cancer cells.

Side effects

Fatigue, rash, itching, diarrhoea and infusion reactions can occur. Immune-mediated inflammation may affect the lungs, bowel, liver, kidneys, heart or hormone-producing glands. Persistent diarrhoea, new cough, chest pain or severe weakness needs prompt assessment.

Important information

Blood tests monitor liver, kidney and thyroid function before and during treatment. Existing autoimmune disease, an organ transplant or previous immune-therapy toxicity changes the risk assessment. Immune complications can start after treatment has ended and may need corticosteroid treatment.